tbuckley/cabot-search huggingface dataset:
Evaluation of predictive factors for thromboembolic events in patients with advanced pancreatic cancer: Evaluation of the CONKO-004 (PROSPECT) study cohort.
Authors: Uwe Pelzer, Sven Bischoff, Jens Stieler, Marianne Sinn, Helmut Oettle, Bernd Dörken, Hanno Riess
Journal: Journal of Clinical Oncology (2012)

4044 Background: Patients (pts) with advanced pancreatic cancer (APC) often suffer from symptomatic thromboembolic events (sVTE). The CONKO-004 trial showed that the low molecular weight heparin (LMWH) enoxaparin reduces sVTE (p&lt;0.05, number needed to treat: 12) without increasing the rate of major bleeding when prophylactically applied. Our goal was to identify predictive factors for sVTE in pts with APC undergoing first-line chemotherapy. Methods: We analyzed the 152 (out of 312) pts randomized in the observation group.SVTE incidence was 9.9%. To identify foremost risk factors we used clinical parameters like performance status, stage, grading, primary or recurrent, gender, age, body mass index, erythropoietin stimulating agents (darbepoetin), as well as baseline laboraty parameters such as creatinine, hemoglobin, WBC, platelets, INR, ptt, CEA, carboanhydrat 19-9, AST, ALT, AP and GGT. The multivariate logistic regression model with forward stepwise selection process was used for this estimation. With reference to a previously proposed scoring system (Khorana et al; Blood 2008) we evaluated the score as well. Results: No single parameter could be isolated demonstrating significant influence on the incidence of sVTE in pts with APC. We verified the Kohrana scoring model with our 152/312 pts. Applying the score to our pts we didn’t discriminate pts between the two high risks groups (Table). Conclusions: Predictive models may help to identify cancer pts at high risk for sVTE to consider preventive anticoagulation. Within a cancer entity at high risk for sVTE such as pts with APC we did not succeed in the identification of single predictive parameters.For pts with APC undergoing first line chemotherapy primary prevention with LMWH should therefore be considered for the whole group of pts for at least three months. [Table: see text]
neural changes before vaso-vagal syncope (letter)
Authors: C. A. Swenne, J. Frederiks, A. V. Bruschke, R. Furlan, S. Piazza, S. Dell'Orto, F. Barbic, A. M. Bianchi, L. T. Mainardi, S. Cerutti, M. Pagani, A. Malliani
Journal: Circulation (1999)
Prognosis Using Planar Imaging in Cardiac Amyloidosis—Reply
Authors: Adam Castaño, Sabahat Bokhari, Mathew S. Maurer
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Risk perceptions in localized breast cancer (BC).
Authors: Pallavi Kumar, Karen Sepucha, Yuchiao Chang, Jeffrey Belkora, Clara N Lee, Ann H. Partridge, Sandra Feibelmann, Beverly Moy
Journal: Journal of Clinical Oncology (2013)

9534 Background: Risk perceptions (RP) play an important role in decision making in localized BC. Little is known about RP in the context of adjuvant (adj) therapy decisions. We examined the accuracy of estimate of absolute benefit of adj therapy among patients (pts) with localized BC and sought to identify determinants of accurate RP. Methods: A cross-sectional survey was conducted in localized (Stage I-III) BC pts within 3 months after surgery at 4 U.S. cancer centers. Pts completed the Decision Quality Instrument, which includes items on BC knowledge, numerical estimates of benefit of adj therapy, and communication with providers. We analyzed pts with Stage I/II and calculated objective estimates of benefit of adj therapy using Adjuvant! Online. Based on published data, an estimate that was +/- 5% of the calculated risk was considered correct. We used multivariable (MV) regression to identify determinants of accuracy including tumor stage, age, adj treatment, education, total knowledge score, and decision involvement. Results: 192/249 (77.1%) pts completed the survey; analyses were limited to 166 pts stage I/II with complete risk estimate data. Mean age was 56.4 years (SD 12.1), 83% of respondents were white, and 58.5% were college graduates. 56.3% had stage I and 43.7% had stage II disease. Most (95.6%) had some type of adj therapy, either endocrine therapy only (43.2%), chemotherapy only (15.3%), or both (32%). On average, pts estimated the absolute benefit of adj therapy to be 31.8% (SD24.9), and this varied by stage (28.4 and 35.9 for stage I and II, p=0.06). The overall estimate for this sample from Adjuvant! Online was 11.8% (SD 7.67) and this varied by stage (8.6/16.0 for stage I/II respectively, p&lt;0.001). Few pts (18.1%) had accurate estimates and the majority (68.3%) overestimated the benefit. In MV logistic regression analysis, only BC knowledge score was associated with accurate estimate of benefit (OR 1.36 95%CI 1.04, 1.8). No other factors were significantly associated with accuracy. Conclusions: Pts with localized BC overestimated the absolute benefit of adj therapy by an average of 20 percentage points. Some pts may be taking on risks of adj therapy without accurate knowledge of the benefits, calling into question whether these decisions are truly informed.
Pharmacokinetics (PK) of blinatumomab and its clinical implications.
Authors: Benjamin Wu, Youssef Hijazi, Andreas Wolf, Christian Brandl, Yu-Nien Sun, Min Zhu
Journal: Journal of Clinical Oncology (2013)

3048 Background: Blinatumomab is an investigational, bispecific, single-chain T cell engaging (BiTE) antibody of 55 kD that targets CD19 on B cells and CD3 on T cells. Blinatumomab induces polyclonal T cell activation and proliferation, resulting in redirected lysis of CD19 + target cells. Comprehensive analysis of its PK and the clinical implications is presented. Methods: PK data from 131 patients enrolled in 3 phase 1 or 2 studies of non-Hodgkin lymphoma (NHL; N=76), relapsed/refractory acute lymphoblastic leukemia (r/r ALL; N=36), and ALL with minimal residual disease (MRD; N=19) were analyzed. Blinatumomab was given by constant IV (cIV) infusion at 0.5, 1.5, 3, 5, 10, 15, 30, 60 and 90 μg/m 2 /d over 4 weeks/cycle. Serum blinatumomab concentrations were assessed using a validated bioassay. PK parameters, including volume of distribution (V), half-life (t 1/2 ) and clearance (CL), were analyzed with noncompartmental methods. CL was derived by dividing infusion rate by blinatumomab concentration at steady state (C ss ). Mean CL from each patient was used to determine disease heterogeneity and for covariate analyses. Effective dose was assessed with PK, in vitroand clinical B cell data. Results: At the doses tested, blinatumomab had linear PK that was stable over time. V (~5 L) approximated that of monoclonal antibodies. Blinatumomab had a t 1/2 of ~2 h, with systemic CL of ~2 L/h. Minute blinatumomab concentrations were detected in the urine of 3 (of 13) NHL patients at a dose of 60 μg/m 2 /d. There was no trend of NHL, r/r ALL or ALL with MRD; CrCL, age, gender, weight, or body surface area (BSA) influencing CL. Preliminary analysis showed comparable mean CL values in patients with CrCL ≥30 mL/min, ranging from 1.9 to 2.6 L/h. To achieve C ss above the in vitro EC 90 value for leukemia cell lines (470 pg/mL) and complete B cell suppression in patients, 15 μg/m 2 /d of blinatumomab given as cIV over 4 weeks/cycle is desired for ALL treatment. Conclusions: Blinatumomab PK was linear, stable, and independent of NHL, r/r ALL or ALL with MRD. Kidney involvement in its excretion was limited at the investigated doses. cIV administration is required due to the short t 1/2 . Flat or BSA-based dosing can be used in adults. A cIV dose of ≥15 μg/m 2 /d provides adequate exposure for ALL treatment. Clinical trial information: NCT00274742, NCT01209826, NCT00560794.
Abstract P179: Effectiveness of CPR Prior to Electrical Shock to Out-of-hospital Cardiac Arrest with Ventricular Fibrillation: A Population-based Study in a Metropolitan Area in Japan “The Utstein Osaka Project”
Authors: Tatsuya Nishiuchi, Yasuaki Hayashino, Shunichi Fukuhara, Taku Iwami, Yasuyuki Hayashi, Kentaro Kajino, Hisashi Ikeuchi, Atsushi Hiraide, Hidekazu Yukioka, Tetsuya Matsuoka
Journal: Circulation (2008)

Objective : To evaluate the effectiveness of CPR prior to electrical shock stratified by the duration from ambulance call to CPR in witnessed out-of-hospital cardiac arrest patients with VF. Study Design : Population-based observational study (May 1, 1998–December 31, 2006). Settings : Osaka, Japan with a population of 8.8 million. Subjects : We analyzed the Utstein Style data on patients who met the following inclusion criteria: witnessed by citizens, 18 years or older, initial recorded cardiac rhythm was VF or pulseless VT, bystander CPR was not performed. Methods : Subjects were divided into three groups according to the duration from the initiation of CPR by ambulance personnel to first electrical shock; immediate shock group: first electrical shock were given in 0–1 minute after CPR was initiated; 2–3 min delayed group: first electrical shock were given in 2–3 minutes after CPR initiated; and ≥4 min delayed group: first electrical shock were given in more than 4 minutes. Main outcome measure : Survival at one month. Results : 909 patients were included in the current analysis. In immediate shock group, survival at one month decreased with an increase in interval between ambulance call and the initiation of CPR. In contrast, 2–3 min delayed group had better prognosis than immediate shock group if CPR was initiated between 8–9 minutes after ambulance call (13% vs. 27% of one month survival; OR 2.50; 95% CI. 1.02–6.00; P=0.045). Conclusion : Our findings suggested that 2–3 minute-delayed electrical shock was associated with better prognosis compared with immediate electrical shock if CPR by ambulance personnel was initiated in 8–9 minutes from ambulance call.
John Tyndall’s Effect on Dermatology
Authors: Patricia M. Richey, Scott A. Norton
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract P2-14-03: Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer
Authors: M Kumar, K Kissoon, AR Abdulai, K De La Torre, M Flowers, E Cohen, S Colen, JB Mercier, M Hurlbert
Journal: Cancer Research (2017)

Abstract Metastatic breast cancer (MBC) remains a terminal illness and is the cause of virtually all breast cancer deaths. The median survival for patients with MBC in the US is approximately 3 years from time of stage IV diagnosis. People living with MBC are in urgent need of new treatment options once current therapies no longer keep the disease under control. Access to new treatments is often through clinical trials. We have developed a novel way to visualize active clinical trials and track trial results. Methods: Clinical trials were queried from Clinicaltrials.gov and the National Cancer Institute. Trials were categorized by breast cancer subtype, line of therapy, hallmark of cancer, sponsor, phase, sample size and compound. A bubble chart was created to display data triplets (x, y, z) corresponding to three continuous variables: x and y to define the position, and z, the radius of each bubble. In our example, x and y coordinates are optimized according to an algorithm that essentially balances the bubble's gravity (i.e., action of moving towards the center of the plot), friction (i.e., velocity decay) and charge (or repulsion/attraction force). This layout is frequently used for network visualization. In addition to x, y and z, it is possible to encode other information. Results: We identified 204 clinical trials actively recruiting patients with MBC. The current webpage (www.mbcalliance.org) displays clinical trial data from 204 clinical trials in six different ways. Trials actively recruiting patients will be updated quarterly. In addition to data triplets (x, y and z) we encoded other information about trials using a color code to add three additional dimensions: phase, breast cancer subtype and sponsor type. When a user hovers over a bubble, key information about the clinical trial extracted from Clinicaltrials.gov is displayed. When a user clicks on the bubble, the user is directed to the corresponding landing page at BreastCancerTrials.org to access detailed trial information. We are employing a similar coding scheme and display characteristics for completed clinical trials results. Conclusions: We have developed a user-friendly, web tool to quickly sort and visualize ongoing clinical trials and results for completed trials to benefit both MBC patients and research scientists. Citation Format: Kumar M, Kissoon K, Abdulai AR, De La Torre K, Flowers M, Cohen E, Colen S, Mercier JB, Hurlbert M. Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-14-03.
Abstract MS2-2: MS2-2 The latest breakthroughs on the translational aspects of DNA repair pathways
Authors: SN Powell
Journal: Cancer Research (2017)

Abstract Genomic instability exists in the majority of human cancer, and there is an underlying DNA repair defect driving the instability in most cases. There are seven defined DNA repair pathways that, when inactive, can produce genome wide patterns of mutations. Current cancer genomics can provide a significant insight into the underlying DNA repair defect. This information can be used to select targeted therapies or suggest a more likely response to immune checkpoint blockade. To use acquired homologous recombination (HR) deficiency as an example of this paradigm, we have found that large scale genomic rearrangements and segmental copy number changes are found in breast cancers without a known germline mutation and see a strong link to biallelic alterations in homologous recombination genes. We detected a genetic etiology of HR deficiency in 90% of studied HR-deficient cases, whereas HR-proficient tumors only showed biallelic HR gene mutations in &amp;lt;7% of cases tested. The goal now is to develop genomic biomarkers that could be used to identify cancer patients who would benefit from therapy with PARP inhibitors and other novel agents, such as those identified by studies of synthetic lethality. Synthetic lethality in human cancer is a developing area of new therapeutic discovery. HR deficiency is thought to be rescued by at least 3 different DNA repair pathways: base-excision repair, translesion synthesis and alternative end joining – all of which are active in proliferating cancer cells. In addition, even the canonical end-joining mechanism of Ku heterodimer binding to any double-stranded end is another component of handling DNA lesion intermediates. The reason for this variety of synthetic lethality has to be different critical DNA lesion intermediates. Knowledge of the DNA damage processing and the proteins involved in the rescue of lesions that would be repaired by HR can provide the basis for the identification of novel targets. I will review our progress in making RAD52 a potential target along with other initiatives for new drug discovery. Citation Format: Powell SN. MS2-2 The latest breakthroughs on the translational aspects of DNA repair pathways [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr MS2-2.
Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation
Authors: Francois Berthoux, Hitoshi Suzuki, Hesham Mohey, Nicolas Maillard, Christophe Mariat, Jan Novak, Bruce A. Julian
Journal: Journal of the American Society of Nephrology (2017)

A prognostic biomarker for IgA nephropathy (IgAN) recurrence after renal transplant is lacking. We followed 96 consecutive first renal transplant recipients with native kidney IgAN (79 men; 92 deceased donors; mean age =48.1 years) on calcineurin inhibitor–based immunosuppression over 10 years for death, allograft failure, and clinicopathologic recurrence (CPR; clinically evident and biopsy-proven). Using time-dependent Cox regression analysis and receiver operating characteristic curves, we assessed prognostic significance of levels of galactose-deficient IgA1 (Gd-IgA1; autoantigen) and Gd-IgA1–specific IgG and IgA autoantibodies in serum obtained at time of transplant or native-kidney IgAN diagnosis (30 patients only). Overall, 13 patients died, 34 kidneys failed (17 due to CPR), and 34 patients developed CPR after a mean interval of 5.8 years. Compared with healthy controls ( n =30), patients had significantly elevated serum Gd-IgA1 levels at diagnosis and transplant, but levels did not associate with any outcome. Patients also had significantly elevated levels of normalized (but not total) serum Gd-IgA1–specific IgG autoantibodies at diagnosis and transplant, and the level at transplant associated with higher risk of CPR (relative risk, 2.68; 95% confidence interval, 1.26 to 5.71; P =0.01; area under the receiver operating characteristic curve, 0.62; 95% confidence interval, 0.51 to 0.74; P =0.05). Normalized Gd-IgA1–specific IgG autoantibody level remained an independent risk factor for CPR in multivariate analysis. Serum Gd-IgA1–specific IgA autoantibody level did not change between diagnosis and transplant or predict outcome. This study emphasizes post-transplant prognostic value of normalized serum IgG antiglycan autoantibody level in patients with IgAN.
Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma.
Authors: Navin Wadehra, Teresa Lin, Timothy Ryan, Ashley Schneider, Allison Pepple, Jeffrey Johnston, James Dalton, Amy Banks, Charles F. Eisenbeis, Raymond Lai, John C. Byrd, Kristie Blum, Robert A. Baiocchi
Journal: Blood (2005)
Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System
Authors: Carlos Montalban, Victor Abraira, Luca Arcaini, Eva Domingo-Domenech, Pablo Guisado-Vasco, Emilio Iannitto, Manuela Mollejo, Estella Matutes, Andrés JM Ferreri, Antonio Salar, Andrea Carpaneto, Ricardo Pérez, Jose Luis Bello, Miguel Hernandez, Dolores Caballero, Miguel A. Piris
Journal: Blood (2011)
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
Authors: Santhosh Satapati, Blanka Kucejova, Joao A.G. Duarte, Justin A. Fletcher, Lacy Reynolds, Nishanth E. Sunny, Tianteng He, L. Arya Nair, Kenneth A. Livingston, Xiaorong Fu, Matthew E. Merritt, A. Dean Sherry, Craig R. Malloy, John M. Shelton, Jennifer Lambert, Elizabeth J. Parks, Ian Corbin, Mark A. Magnuson, Jeffrey D. Browning, Shawn C. Burgess
Journal: Journal of Clinical Investigation (2016)
A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
Authors: Nathan Fowler, Raisa M. Pinto, Chan Yoon Cheah, Sattva S. Neelapu, Francesco Turturro, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Luis E. Fayad, Sheryl Forbes, Janine Khan, Lei Feng, Felipe Samaniego, Loretta Nastoupil
Journal: Blood (2015)
<i>BRAF</i> V600E Mutation in Involuting Nevus in a Patient Treated With Vemurafenib
Authors: José Francisco Millán-Cayetano, Inés Fernández-Canedo, Nuria Blázquez-Sánchez, Rafael Fúnez-Liébana, Magdalena de Troya-Martín
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience.
Authors: Uday Popat, Marcos J de Lima, Touch Ativitavas, Gabriela Rondon, Leandro de Padua Silva, Ebru Koca, Weiqing Zhang, Amin Alousi, Paolo Anderlini, Sergio A. Giralt, Chitra M. Hosing, Roy Jones, Partow Kebriaei, Issa Khouri, Yago Nieto, Muzaffar H. Qazilbash, Borje S. Andersson, Richard Champlin
Journal: Blood (2008)